Table 1. Group characteristics by the CCR5 genotype.
| CCR5 Δ32/wt genotype | CCR5 wt/wt genotype | total | CCR5 Δ32/wt genotype frequency (%) | p value | |
| No. of patients* (%) | 71 (14.0) | 436 (86.0) | 507 (100) | 14.0 | n/a |
| Gender | |||||
| female (% of total) | 14 (2.76) | 130 (25.64) | 144 (28.4) | 9.72 | 0.08 |
| male (% of total) | 57 (11.24) | 306 (60.36) | 362 (71.6) | 15.7 | |
| Clinical category at diagnosis | |||||
| A (% of total) | 44 (8.92) | 156 (31.64) | 200 (40.57) | 22.0 | 0.003 |
| B (% of total) | 14 (2.84) | 164 (33.27) | 178 (36.11) | 7.87 | |
| C (% of total) | 13 (2.64) | 102 (20.69) | 115 (23.33) | 11.3 | |
| Likely infection mode | |||||
| MSM (% of total) | 18 (3.58) | 94 (18.6) | 112 (22.27) | 16.07 | 0.07 |
| Heterosexual (% of total) | 16 (3.18) | 120 (23.86) | 136 (27.04) | 11.76 | |
| Injection Drug Use (% of total) | 36 (7.16) | 218 (43.34) | 254 (50.50) | 14.17 | |
| History of cART during follow-up | |||||
| cART >1 month (% of total) | 55 (10.93) | 368 (73.16) | 423 (84.1) | 13.0 | 0.1 |
| Never on cART or <1 month (% of total) | 16 (3.18) | 64 (12.72) | 80 (15.9) | 20.0 | |
| History of Hepatitis C | |||||
| HIV/HCV coinfected (% of total) | 40 (8.62) | 224 (48.28) | 264 (56.9) | 12.0 | 0.32 |
| HIV monoinfection (% of total) | 24 (5.17) | 176 (38.93) | 200 (43.1) | 15.5 | |
| Diagnosis of AIDS during follow-up | |||||
| AIDS diagnosed (% of total) | 24 (4.73) | 169 (33.33%) | 193 (38.07) | 12.44 | 0.42 |
| AIDS-free (% of total) | 47 (9.27) | 267 (52.66) | 314 (61.93) | 14.97 | |
| Mortality | |||||
| All-cause death (% of total) | 7 (1.38) | 86 (16.96) | 93 (19.13) | 7.53 | 0.05 |
| Aids related death (% of total) | 5 (0.98) | 48 (9.46) | 53 (10.45) | 7.58 | 0.31 |
| Non-AIDS related death (% of total) | 2 (0.03) | 38 (7.45) | 40 (7.89) | 5.0 | 0.07 |
| Immunologic and virologic characteristics | |||||
| Median baseline lymphocyte CD4 count (IQR) (cells/µl) | 280 (44–539) | 209 (64–417) | 229 (63.5–417.5) | n/a | 0.2 |
| Median nadir lymphocyte CD4 count (IQR) (cells/µl) | 171 (41–332) | 138 (47–300) | 147 (46–303) | n/a | 0.33 |
| Median zenith lymphocyte CD4 count (IQR) (cells/µl) | 539 (380–810) | 520 (316–780) | 522 (322–780) | n/a | 0.42 |
| Median baseline viral load (IQR) (copies/ml) | 85200 (21600–310000) | 70500 (14000–320000) | 74000 (14222–315000) | n/a | 0.94 |
n/a – non-applicable. Sample sizes vary due to data availability: CCR5 genotype, gender, AIDS diagnosis – 507 persons, HCV co-infection status - 464 persons, transmission route and history of antiretroviral treatment – 503 persons, HIV infection stage at diagnosis – 489 persons, baseline viral load (log copies/ml) – 288 persons, baseline lymphocyte CD4 count (cells/µl) – 488 persons, nadir lymphocyte CD4 count (cells/µl) – 494 persons, zenith lymphocyte CD4 count (cells/µl) – 499 persons, time with lymphocyte CD4 count >500 cells/µl – 500 persons, latest lymphocyte CD4 count – 504 persons.